This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Basic classification information | |
|---|---|
| ICD-10 | E77.1 |
| Special Copayment Reduction code | V117 |
| Main Korean name | Fucosidosis |
| Synonyms | Alpha-L-fucosidase deficiency, Fucosidosis, alpha-fucosidase deficiency |
| 1. History | 2. Causes |
| 3. Genetics | 4. General epidemiology |
| 5. Pathophysiology | 6. Symptoms |
| 7. Signs | 8. Screening |
| 9. Diagnosis | 10. Treatment |
| 11. Prognosis | 12. Prevention |
| 13. References | |
Fucosidosis was first described in 1966 by Van Hoof and Hers. They found accumulation of fucose-containing glycolipids and glycoproteins in the tissues of pediatric patients with psychomotor developmental delay and distinctive facies and reported it as a new lysosomal storage disease. Subsequently, in 1971, Durand et al. demonstrated that alpha-L-fucosidase activity was deficient, establishing its nature as an enzyme deficiency.
Initially it was classified by clinical severity into type 1 (severe, early onset) and type 2 (mild, late onset), but this distinction is now understood to represent the two extremes of a single disease spectrum. In the 1970s, it was reported that skin angiokeratomas (angiokeratoma corporis diffusum) are observed in some patients, raising the need for caution in the differential diagnosis from Fabry disease.
The causative gene, FUCA1, was shown in the 1990s to be located on chromosome 1p36.11, and many pathogenic variants have since been reported. A relatively high incidence has been reported in Italy and Spain, which is presumed to be due to a founder effect.
Fucosidosis is caused by a genetic deficiency of the lysosomal enzyme alpha-L-fucosidase (EC 3.2.1.51). This enzyme is responsible for cleaving alpha-L-fucose residues located at the nonreducing ends of glycoproteins, glycolipids, and oligosaccharides. Fucose is a key component of N-linked or O-linked glycans and is found in blood group antigens (ABH, Lewis antigens), selectin ligands, and various cell surface glycoproteins.
When enzyme activity is lost or markedly reduced because of pathogenic variants in the FUCA1 gene, breakdown products of fucose-containing glycoproteins and glycolipids progressively accumulate in lysosomes. To date, more than 36 biallelic pathogenic variants have been reported; missense/nonsense substitutions are the most common, and small deletions and splice site variants have also been reported.
The mode of inheritance is autosomal recessive. Carriers have no clinical symptoms, and their enzyme activity is about 50% of normal.
The FUCA1 gene is located on chromosome 1p36.11 and consists of 8 exons. The mature protein is an acidic alpha-L-fucosidase of 461 amino acids that functions as a homotetramer in the lysosome. Notably, in humans there is an isoenzyme gene called FUCA2 in addition to FUCA1, but FUCA2 is an alkaline fucosidase unrelated to lysosomal function. Therefore, only FUCA1 deficiency causes the disease.
Some regionally clustered variants are known. Specific founder mutations have been identified in Italian and Spanish patients, and variant screening is highly efficient in these populations. In contrast, patients from other regions often have diverse private mutations. Phenotype-genotype correlation is incomplete, and residual enzyme activity is known to predict clinical severity to some extent. Molecular diagnosis is performed by Sanger sequencing or NGS panels.
Fucosidosis is a very rare disease worldwide, with an estimated incidence of less than 1 per about 1 million live births. The number of patients reported worldwide to date is known not to exceed 200. A relatively high incidence has been reported in southern Italy (especially the Calabria region) and parts of Spain, which is attributed to a founder effect.
There is no sex difference, and it occurs equally in males and females. Age at diagnosis varies by clinical phenotype, but it is usually first suspected and diagnosed in early childhood (ages 1–5). In rapidly progressive severe forms, symptoms may appear within 6 months to 1 year after birth. Rarely, mild forms diagnosed after school age or in adulthood have also been reported. Because the number of patients worldwide is very small, clinical research is difficult and data on the natural history are limited.
Alpha-L-fucosidase cleaves fucose residues in terminal alpha-1,2 linkages or alpha-1,3/4/6 linkages of glycans. When this enzyme is deficient, breakdown of fucose-containing glycoproteins, glycolipids, and oligosaccharides is impaired, and these substrates gradually accumulate in lysosomes. In particular, the terminal and core fucose residues of N-linked or O-linked glycans of glycoproteins are the main targets of accumulation.
The accumulated substrates cause lysosomal swelling and cellular dysfunction in almost all tissues, including the brain, liver, spleen, skin, heart, and skeleton. In the nervous system, lysosomal enlargement and apoptosis of neurons lead to progressive neurodegeneration. In the skin, lysosomal substrate accumulation in vascular endothelial cells forms angiokeratomas. Accumulation in sweat glands leads to increased excretion of oligosaccharides and glycopeptides in sweat, which is used as a diagnostic clue.
Secondary cellular pathology resulting from lysosomal dysfunction—impaired autophagy, mitochondrial dysfunction, activation of inflammatory pathways—acts in combination to produce the clinical picture of multiorgan involvement.
The clinical picture of fucosidosis varies with severity but is characterized by a combination of progressive neurological deterioration and somatic symptoms.
Psychomotor developmental delay is the most prominent symptom; children appear normal early after birth, and then achievement of developmental milestones is gradually delayed. This is followed by progressive loss of acquired skills (neurodegeneration), and seizures, ataxia, dystonia, and dysphagia progress. Language development is severely delayed or lost, and intellectual disability gradually worsens.
Growth retardation, multiple skeletal dysplasia (coarse facial features, dysostosis multiplex), scoliosis, and joint stiffness appear. Motor development is delayed by hypotonia, which later converts to spasticity.
Recurrent upper and lower respiratory tract infections are common. Airway narrowing due to thickening of upper airway soft tissues and obstructive sleep apnea may also occur.
Hepatosplenomegaly and umbilical and inguinal hernias are present. Increased sweating (diaphoresis) is reported in some patients.
Coarse facies: a large head, low nasal bridge, thick lips, large tongue, and wide spacing between the eyebrows are observed. Facial features become more pronounced with age.
Skin angiokeratomas are particularly prominent in the mild (late-onset) form and appear as small, dark red skin lesions distributed around the umbilicus, perineum, inner thighs, buttocks, and elsewhere. Because they are also observed in Fabry disease and sialidase deficiency (galactosialidosis), differential diagnosis is necessary. The presence of skin angiokeratomas is an important diagnostic clue in the milder forms.
Corneal opacity is not uncommon, and retinal vascular abnormalities are sometimes observed on fundus examination.
Hypotonia appears early, and spasticity, seizures, and progressive decline in consciousness appear later. Brain MRI shows cerebral atrophy and white matter signal abnormalities.
There is currently no standard newborn screening program for fucosidosis, but screening methods using DBS-based measurement of alpha-L-fucosidase activity have been studied. Measurement of enzyme activity using a fluorescent substrate is the simplest screening tool.
Qualitative and quantitative analysis of urine oligosaccharides is used for first-line screening. In the urine of patients with fucosidosis, excretion of fucose-containing oligosaccharides and glycopeptides is markedly increased, and this is analyzed by thin-layer chromatography (TLC) or high-performance liquid chromatography (HPLC). Urine oligosaccharide analysis is also useful for differentiation from other glycoprotein storage diseases (mannosidosis, sialidase deficiency, aspartylglucosaminuria, etc.).
When there is clinical suspicion—the combined findings of coarse facies, neurodegeneration, and angiokeratomas—measurement of leukocyte or serum alpha-L-fucosidase activity should be performed immediately.
Confirmation is made by demonstrating that alpha-L-fucosidase activity in peripheral blood leukocytes, serum, or cultured skin fibroblasts is markedly reduced to less than 1–10% of normal controls. Fluorometry using a fluorescent substrate (4-methylumbelliferyl-alpha-L-fucopyranoside) is the standard.
FUCA1 gene sequencing (Sanger sequencing or NGS panel) to identify pathogenic variants on both alleles. Variant identification is essential for prenatal diagnosis and carrier testing. Large deletions/duplications are detected by chromosomal microarray (CMA).
To date, there is no approved specific treatment for fucosidosis, and treatment centers on symptom management and supportive care.
Some reports have suggested that early hematopoietic stem cell transplantation slows disease progression. It is known that the better the neurological function before transplantation, the better the effect, but the number of cases to date is very small and long-term follow-up data are lacking, so clinical evidence is limited.
Enzyme replacement therapy (ERT) and gene therapy are theoretically possible, but clinical-stage research is still at an early stage. Substrate reduction therapy (SRT) approaches are also being explored at the research level.
The prognosis of fucosidosis varies with the clinical phenotype. In the severe (early-onset) form, progressive neurodegeneration advances rapidly, and many patients enter a vegetative state or die before age 10. The main causes of death are aspiration pneumonia, recurrent respiratory infections, and cardiopulmonary failure.
In the mild (late-onset) form, angiokeratomas are the main skin manifestation, intellectual function is reduced only mildly to moderately, and survival into adulthood has been reported. Some patients survive into their 30s–40s or beyond. Because current treatment is limited to supportive care, the top priorities are preventing complications and maintaining quality of life through early diagnosis and multidisciplinary management. The development of specific therapies is expected to play a decisive role in improving prognosis in the future.
With autosomal recessive inheritance, primary prevention is based on genetic counseling and prenatal diagnosis. The recurrence risk for siblings of a patient is 25%, and parental carrier testing and prenatal diagnosis are recommended. Prenatal diagnosis is performed by measuring alpha-L-fucosidase activity or by FUCA1 molecular analysis in fetal cells after CVS (10–12 weeks of gestation) or amniocentesis (16–18 weeks of gestation).
Preimplantation genetic diagnosis (PGT-M) is also an option when the familial pathogenic variant has been identified. In regions with relatively high incidence, such as southern Italy and parts of Spain, expanded carrier screening programs may be useful. Minimizing secondary complications through multidisciplinary management after early diagnosis is the core of secondary prevention.